Incyte (INCY) reported Q1 adjusted earnings Tuesday of $1.16 per diluted share, up from $0.58 a year earlier.
Analysts polled by FactSet expected $0.98.
Revenue for the quarter ended March 31 was $1.05 billion, up from $880.9 million a year earlier.
Analysts surveyed by FactSet expected $985.1 million.
The pharmaceutical company said it expects fiscal 2025 Jakafi net product revenue of $2.95 billion to $3 billion, compared with a prior outlook of $2.93 billion to $2.98 billion. Incyte continues to expect annual Opzelura net product revenue of $630 million to $670 million and other oncology net product revenue of $415 million to $455 million.
Shares of the company were 3.3% higher in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.